Clinical rationale for the use of various teraflex formulations in osteoarthrosis
https://doi.org/10.14412/1996-7012-2010-639
Abstract
The paper provides a rationale for using Teraflex with a manifest symptom-modifying effect in patients with osteoarthritis (OA). It is noted that
the use of agents that are potentially able to modify cartilage metabolic processes attracts attention above all due to the possibility of achieving
a permanent reduction in the magnitude of pain and inflammation in OA and their safety in its treatment. Teraflex components, such as chondroitin
sulfate and glucosamine, are shown to have the effect, while slower, that is comparable with that of nonsteroidal anti-inflammatory drugs
(NSAIDs) on pain and articular function, on the one hand, and to be capable to affect the course of the disease and its outcome, by slowing
down the progression of the disease, on the other. It is stated that the long-term (1-2-year) use of Teraflex in patients with a not more than
36-month history of OA makes it possible to improve quality of life and to reduce needs for NSAIDs. Therapeutic effectiveness can be enhanced
by combining the oral and topical formulations of Teraflex.
the use of agents that are potentially able to modify cartilage metabolic processes attracts attention above all due to the possibility of achieving
a permanent reduction in the magnitude of pain and inflammation in OA and their safety in its treatment. Teraflex components, such as chondroitin
sulfate and glucosamine, are shown to have the effect, while slower, that is comparable with that of nonsteroidal anti-inflammatory drugs
(NSAIDs) on pain and articular function, on the one hand, and to be capable to affect the course of the disease and its outcome, by slowing
down the progression of the disease, on the other. It is stated that the long-term (1-2-year) use of Teraflex in patients with a not more than
36-month history of OA makes it possible to improve quality of life and to reduce needs for NSAIDs. Therapeutic effectiveness can be enhanced
by combining the oral and topical formulations of Teraflex.
References
1. <div><p>Рациональная фармакотерапия ревматических заболеваний. Рук-во для практикующих врачей. Под ред. В.А. Насоновой, Е.Л. Насонова. М.: Литтерра, 2003;507 с.</p><p>Smith M.M., Ghosh P. Osteoarthritis: Current status and future directions. APLAR J Rheum 1998;2:27-53.</p><p>Croft P., Coggon D., Crudas M. et al. Osteeoarthritis of the hip: an occupational disease of farmers. BMJ 1992;304(6837):1269-72.</p><p>Cooper C. Occupational activity and the risk of Osteoarthritis. J Rheumatol 1995;22(Suppl.43):10-2.</p><p>Lane N.E., Hochberg M.C., Pressman A. et al. Recreational physical activity and the risk of Osteoarthritis of the hip in elderly women. J Rheumatol 1999;26(4):849-54.</p><p>Mohtai M., Smith R.L., Schurman D.J. et al. Expression of 92-kD type IV collagenase/ gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993;92(1):179-85.</p><p>Lawrence R.C., Brummer J.M., Bier F. Osteoarthritis prevalence in the population and relationship between symptoms and X-ray changes. Ann Rheum Dis 1966;25:1-24.</p><p>Lawrence R.C., Helmick C.G., Arnett F.C. et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 1998;41:778-99.</p><p>Беневоленская Л.И., Бржезовский М.М. Эпидемиология ревматических болезней. М.: Медицина, 1988;237 с.</p><p>Jordan K.M., Arden N.K., Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.</p><p>Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ 2008;16(7):476-80</p><p>Van Dijk G.M., Veenhof C., Schellevis F. et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008;9:95.</p><p>Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М., 2006;88 с.</p><p>Blot L., Marcelis A., Devogelaer J.P. et al. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human articular cartilage. Br J Pharmacol 2000;131:1413-21.</p><p>Leeb B.F., Schweitzer H., Montag K. et al. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.</p><p>McAlindon T.E., LaValley M.P., Gulin J.P. et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.</p><p>Richy F., Bruyere O., Ethgen O. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-22.</p><p>Поворознюк В.В. Глюкозамин и хондроитин в лечении остеоартроза: данные литературы и результаты собст- венных исследований. РМЖ 2006;14(4):1-5.</p><p>Baici A., Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chem Biol Interaction 1984;51:1-11.</p><p>Lippielo L., Grande D. In vitro chondroprotection of glucosamine and chondroitin sulfate in a rabbit model of a OA and demonstration of metabolic synergy on chondrocyte in vitro. Ann Rheum Dis 2000;59(Suppl.1):266.</p><p>Yaron I., Shirasi R., Judovich R. et al. Chondroitin sulfate inhibits prostaglandin E2 production in synovial cell cultures and reverses IL-1 inhibition of cartilage synthesis. Ann Rheum Dis 2000;59(Suppl.1):265.</p><p>Reveliere D., Mentz F., Merie-Beral H. et al. Protective effect of chondroitin 4,6-sulfate on apoptosis of rabbit articular chondrocytes - preliminary results. In: Mautone G., Tajana E., Rovati S., Vacher D., eds. New appoaches in OA. Zurich: Litera Rheumatologica 24, EULAR 1999;15-20.</p><p>Беневоленская Л.И., Алексеева Л.И., Зайцева Е.М. Эффективность препарата Терафлекс у больных с остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). РМЖ 2005;13(8):525-7.</p><p>Lippielo L., Woodword J., Karpman D. et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte and rabbit instability model osteoartrosis. Arthr Rheum 1999;Suppl. 42:256.</p><p>Houpt J.B., McMillan R. et al. Effect of treatment of glucosamine hydrochloride in the treatment of pain in osteoarthritis of the knee. J Rheum 1998;25(Suppl.52):8.</p><p>Лила А.М., Мазуров В.И., Шидловская О.В. и др. Терафлекс в комплексной терапии остеоартроза коленных суставов и позвоночника (результаты клинического исследования). РМЖ 2005;13(24):1618-22.</p><p>Маличенко С.Б., Колесова И.Р. Изучение клинической эффективности и переносимости препарата Терафлекс (глюкозамин гидрохлорид - 500 мг и натрий хондроитин сульфат - 400 мг) при суставном синдроме у женщин в физиологической и хирургической менопаузе. Отчет. М., 2005.</p><p>Алексеева Л.И. Результаты открытого сравнительного рандомизированного исследования эффективности и безопасности 2 схем лечения препаратом Терафлекс у пациентов с остеоартрозом коленного сустава. Клиническое исследование. РМЖ 2008;16(5):316-9.</p><p>Алексеева Л.И. Открытое рандомизированное сравнительное исследование эффективности и безопасности препарата Терафлекс Адванс по сравнению с препаратами Терафлекс и ибупрофен у пациентов с остеоартрозом коленных суставов. Научный отчет. М., 2006-2007.</p><p>Поворознюк В.В. Эффективность препарата Терафлекс Адванс в лечении болевого синдрома при остеоартрозе коленных суставов. Здоровье Украины 2007;1-3.</p><p>Поворознюк В.В. Применение крема Терафлекс М в комбинации с капсулами Терафлекс у больных гонартрозом. Пробл остеол 2006;4.</p><p>Светлова М.С. Терафлекс в лечении гонартроза ранних стадий. РМЖ 2010;9:592-4.</p></div><br />
Review
For citations:
Chichasova NV. Clinical rationale for the use of various teraflex formulations in osteoarthrosis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2010;4(4):59-64. (In Russ.) https://doi.org/10.14412/1996-7012-2010-639
Views:
1786
Email this article 